Agios Pharmaceuticals, Inc. (AGIO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $2.16B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brian Goff |
| IPO Date | 2013-07-24 | CAGR | 6.68% |
| Employees | 540 | Website | www.agios.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $2.39B | P/E | -5.02 | Forward P/E | -7.97 | PEG | — |
| P/S | 20648.21 | P/B | 1205.5 | P/CF | -3542.44 | P/FCF | -3542.44 |
| Sales | $66.05M | Sales 1Y | 78.34% | Sales 3Y | 247.31% | Sales 5Y | -43.11% |
| EPS | $-7.25 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 3.9% | EPS QoQ | -8.65% | Sales QoQ Avg | 26.27% | EPS QoQ Avg | 3.01% |
| Gross Margin | 82.07% | Operating Margin | -719.97% | Profit Margin | -639.84% | ROCE | -42.23% |
| ROA | -36% | ROE | -34% | Altman Z Score | 15.74 | Piotroski Score | 3 |
| Current Ratio | 14.19 | Quick Ratio | 13.59 | Cash Ratio | 1.93 | Op. CF Ratio | -2.02 |
| Debt/Equity | 0.03 | Debt/Assets | 0.03 | Lt Debt/Equity | 0.02 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | 0.34 | Asset Turnover | 0.06 | Receivables Turnover | 4.09 |
| Enterprise Value | $2.39B | P/E Ratio | -5.02 |
| Forward P/E | -7.97 | PEG Ratio | — |
| P/S Ratio | 20648.21 | P/B Ratio | 1205.5 |
| P/CF Ratio | -3542.44 | P/FCF Ratio | -3542.44 |
| EPS | $-7.25 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 78.34% | Gross Margin | 0.82% |
| Operating Margin | -7.2% | Profit Margin | -6.4% |
| ROE | -0.34% | ROA | -0.36% |
| ROCE | -0.42% | Current Ratio | 14.19 |
| Quick Ratio | 13.59 | Cash Ratio | 1.93 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | 15.74 | Piotroski Score | 3 |
Agios Pharmaceuticals, Inc. (AGIO) valuation & financials
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.16B and trades at a price-to-earnings ratio of -5.0. It operates in the Healthcare sector (Biotechnology).
Agios Pharmaceuticals, Inc.'s revenue grew +78.3% over the last year.
Agios Pharmaceuticals, Inc.'s next earnings report is scheduled for July 30, 2026; analysts estimate EPS of $-1.67.
Agios Pharmaceuticals, Inc. (AGIO) — frequently asked questions
When does Agios Pharmaceuticals, Inc. (AGIO) report earnings next?
Agios Pharmaceuticals, Inc. is expected to report earnings on July 30, 2026. Analysts estimate EPS of $-1.67.
What is Agios Pharmaceuticals, Inc.'s market cap?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.16B.
What is AGIO's P/E ratio?
Agios Pharmaceuticals, Inc. trades at a price-to-earnings ratio of -5.0, with trailing twelve-month EPS of $-7.25.
How fast is Agios Pharmaceuticals, Inc. growing?
Agios Pharmaceuticals, Inc.'s revenue grew +78.3% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)